Literature DB >> 10531408

Tight association of the human Mel(1a)-melatonin receptor and G(i): precoupling and constitutive activity.

F Roka1, L Brydon, M Waldhoer, A D Strosberg, M Freissmuth, R Jockers, C Nanoff.   

Abstract

If stably expressed in human embryonic kidney (HEK)293 cells, the human Mel(1a)-melatonin receptor activates G(i)-dependent, pertussis toxin-sensitive signaling pathways, i.e., inhibition of adenylyl cyclase and stimulation of phospholipase Cbeta; the latter on condition that G(q) is coactivated. The antagonist luzindole blocks the effects of melatonin and acts as an inverse agonist at the Mel(1a) receptor in both intact cells and isolated membranes. This suggests that the Mel(1a) receptor is endowed with constitutive activity, a finding confirmed on reconstitution of the Mel(1a) receptor with G(i). Because the receptor density is in the physiological range, constitutive activity is not an artifact arising from overexpression of the receptor. In addition, the following findings indicate that the Mel(1a) receptor forms a very tight complex with G(i) which can be observed both in the presence and absence of an agonist. 1) In intact cells and in membranes, high-affinity agonist binding is resistant to the destabilizing effect of guanine nucleotides. 2) The ability to bind an agonist with high affinity is preserved even after exposure of the cells to pertussis toxin, because a fraction of G(i) is inaccessible to the toxin in cells expressing Mel(1a) receptors (but not the A(1)-adenosine receptor, another G(i)-coupled receptor). 3) An antiserum directed against the Mel(1a) receptor coprecipitates G(i) even in the absence of an agonist. We therefore conclude that the Mel(1a) receptor is tightly precoupled and that its constitutive activity may play a role in pacing the biological clock, an action known to involve the melatonin receptors in the suprachiasmatic nucleus.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10531408     DOI: 10.1124/mol.56.5.1014

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  25 in total

Review 1.  GPCR and G proteins: drug efficacy and activation in live cells.

Authors:  Jean-Pierre Vilardaga; Moritz Bünemann; Timothy N Feinstein; Nevin Lambert; Viacheslav O Nikolaev; Stefan Engelhardt; Martin J Lohse; Carsten Hoffmann
Journal:  Mol Endocrinol       Date:  2009-02-05

2.  Constitutive activity of the A2A adenosine receptor and compartmentalised cyclic AMP signalling fine-tune noradrenaline release.

Authors:  Edin Ibrisimovic; Helmut Drobny; Qiong Yang; Thomas Höfer; Stefan Boehm; Christian Nanoff; Klaus Schicker
Journal:  Purinergic Signal       Date:  2012-04-05       Impact factor: 3.765

Review 3.  Understanding melatonin receptor pharmacology: latest insights from mouse models, and their relevance to human disease.

Authors:  Gianluca Tosini; Sharon Owino; Jean-Luc Guillaume; Ralf Jockers
Journal:  Bioessays       Date:  2014-06-05       Impact factor: 4.345

4.  Molecular organization and dynamics of the melatonin MT₁ receptor/RGS20/G(i) protein complex reveal asymmetry of receptor dimers for RGS and G(i) coupling.

Authors:  Pascal Maurice; Avais M Daulat; Rostislav Turecek; Klara Ivankova-Susankova; Francesco Zamponi; Maud Kamal; Nathalie Clement; Jean-Luc Guillaume; Bernhard Bettler; Céline Galès; Philippe Delagrange; Ralf Jockers
Journal:  EMBO J       Date:  2010-09-21       Impact factor: 11.598

Review 5.  The serotonin 5-HT7 receptors: two decades of research.

Authors:  Evelien Gellynck; Karen Heyninck; Kjetil W Andressen; Guy Haegeman; Finn Olav Levy; Peter Vanhoenacker; Kathleen Van Craenenbroeck
Journal:  Exp Brain Res       Date:  2013-09-17       Impact factor: 1.972

Review 6.  [Molecular and genetic aspects of idiopathic scoliosis. Blood test for idiopathic scoliosis].

Authors:  A Moreau; M-Y Akoumé Ndong; B Azeddine; A Franco; P H Rompré; M-H Roy-Gagnon; I Turgeon; D Wang; K M Bagnall; B Poitras; H Labelle; C-H Rivard; G Grimard; J Ouellet; S Parent; F Moldovan
Journal:  Orthopade       Date:  2009-02       Impact factor: 1.087

Review 7.  Molecular mechanisms of melatonin's inhibitory actions on breast cancers.

Authors:  Sara Proietti; Alessandra Cucina; Russel J Reiter; Mariano Bizzarri
Journal:  Cell Mol Life Sci       Date:  2012-09-25       Impact factor: 9.261

Review 8.  Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?

Authors:  R Jockers; P Maurice; J A Boutin; P Delagrange
Journal:  Br J Pharmacol       Date:  2008-05-19       Impact factor: 8.739

9.  The end of a myth: cloning and characterization of the ovine melatonin MT(2) receptor.

Authors:  F Cogé; S P Guenin; I Fery; M Migaud; S Devavry; C Slugocki; C Legros; C Ouvry; W Cohen; N Renault; O Nosjean; B Malpaux; P Delagrange; J A Boutin
Journal:  Br J Pharmacol       Date:  2009-10-08       Impact factor: 8.739

10.  Role of MT1 melatonin receptors in methamphetamine-induced locomotor sensitization in C57BL/6 mice.

Authors:  Anthony J Hutchinson; Jason Ma; Jiabei Liu; Randall L Hudson; Margarita L Dubocovich
Journal:  Psychopharmacology (Berl)       Date:  2013-08-11       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.